Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This multi-centre study will compare the acceptability, feasibility, cost and incremental
cost-effectiveness of intermittent preventive treatment (IPTp) with
dihydroartemisinin-piperaquine (DP) with or without azithromycin to the current strategy of
IPTp with sulphadoxine-pyrimethamine (SP) to prevent malaria, sexually transmitted and
reproductive tract infections in HIV-uninfected pregnant women (IMPROVE).
Phase:
Phase 4
Details
Lead Sponsor:
Liverpool School of Tropical Medicine
Collaborators:
Kenya Medical Research Institute Kilimanjaro Christian Medical Centre, Tanzania London School of Hygiene and Tropical Medicine National Institute for Medical Research, Tanzania University of Bergen University of Malawi College of Medicine
Treatments:
Fanasil, pyrimethamine drug combination Piperaquine Pyrimethamine Sulfadoxine